Helicobacter pylori infection
Conditions
Interventions
Group A:ilaprazole 5mg + amoxicillin 1g + clarithromycin 500mg + bismuth potassium citrate 220mg, Bid
Group B:ilaprazole 5mg Bid + amoxicillin 1g Tid
Group C:ilaprazole 10?mg Bid + amoxicillin 1g Tid
Sponsors
Beijing Huaxin Hospital (The First Affiliated Hospital of Tsinghua University)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Patients with positive 13C-urea breath test (13C-UBT), rapid urease test of gastric mucosal tissue, or positive pathological staining; (2) Patients who have not previously received H.pylori eradication therapy; (3) Age 18-70, both genders; (4) Sufficiently informed and agreed to participate in this study.
Exclusion criteria
Exclusion criteria: (1) Patients who have taken drugs that may affect the results of this study, such as PPIs, H2 receptor antagonists, bismuth preparations, or antibiotics, in the 4 weeks before enrollment; (2) Patients diagnosed with digestive tract tumors; (3) Patients who have undergone upper gastrointestinal surgery; (4) Patients with severe accompanying diseases who cannot tolerate treatment; (5) Patients with severe liver or kidney dysfunction, cardiovascular and cerebrovascular diseases, mental illness; (6) Any drug allergy or intolerance; (7) Patients who were pregnant or lactating; (8) Patients with other medical conditions that may increase adverse treatment reactions (e.g., alcohol abuse).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate of Helicobacter pylori; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event rates;Patient compliance; | — |
Countries
China
Contacts
Public ContactCheng Yanli
Beijing Huaxin Hospital (The First Affiliated Hospital of Tsinghua University)
Outcome results
None listed